Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph early_phase_1
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 21 (33.3%)

Trials by Status

not_yet_recruiting133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedearly_phase_1

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

NCT06065189
not_yet_recruitingphase_2

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

NCT07489196
completedphase_1

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

NCT06291961

Clinical Trials (3)

Showing 3 of 3 trials
NCT06065189Early Phase 1

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Completed
NCT07489196Phase 2

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Not Yet Recruiting
NCT06291961Phase 1

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3